Considering that TCPTP levels are markedly higher in lymphoid and bone marrow tissues than in other sites, whereas PTP1B is more widely expressed and is present especially in tissues involved in glucose homeostasis, it was suggested that inhibitors more selectively directed to TCPTP might be potentially safer for cancer immunotherapy. This evidence concerns the gene PTPN2 and cancer.